Privia Health Group (PRVA) AI Stock Analysis

• Market Cap: $3.03B
• Dividend Yield: N/A
• Average Volume (3M): 902.05K
• Price to Earnings (P/E): 211.2
• Beta (1Y): 0.76
• Revenue Growth: 19.01%
• EPS Growth: 38.68%
• Country: US
• Employees: 1,140
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.05
• Shares Outstanding: 122,729,930
• 10 Day Avg. Volume: 791,959
• 30 Day Avg. Volume: 902,055
• PEG Ratio: -4.06
• Price to Book (P/B): 3.68
• Price to Sales (P/S): 1.34
• P/FCF Ratio: 21.36
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: 1.28
• Enterprise Value/Gross Profit: 12.95
• Enterprise Value/Ebitda: 62.47
• 1Y Price Target: $29.83
• Price Target Upside: 27.32% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 75 Outperform
• Price Target: $24.50 ▲(4.57% Upside)

Privia Health Group's strong financial performance and positive earnings call are key strengths, supported by robust revenue growth and strategic expansion. However, the high P/E ratio and absence of a dividend yield present valuation concerns. Technical indicators show moderate bullish momentum, contributing to a balanced overall score.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market expansion and increased adoption of services, enhancing long-term business stability.

Strategic Acquisitions

Strategic acquisitions expand market presence and service offerings, positioning the company for sustained growth and competitive advantage.

Cash Position

A strong cash position with no debt enhances financial flexibility, enabling strategic investments and resilience against economic fluctuations.

Negative Factors

EBIT Margin Fluctuations

Inconsistent EBIT margins can signal operational inefficiencies, potentially impacting profitability and financial predictability over time.

Capitation Model Challenges

Challenges in the capitation model may affect revenue stability and require strategic adjustments to mitigate potential financial impacts.

Conservative Q4 Guidance

Conservative guidance suggests potential short-term financial pressures, which could impact investor confidence and strategic planning.

Privia Health Group Business Overview & Revenue Model

Company Description

Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. was a former subsidiary of Brighton Health Group Holdings, LLC.

How the Company Makes Money

Privia Health generates revenue through a multi-faceted model that primarily includes service fees from healthcare providers who utilize its technology and management services. Key revenue streams consist of subscription fees for its platform, performance-based incentives tied to value-based care initiatives, and fees for ancillary services such as care coordination and patient engagement tools. Strategic partnerships with payers and healthcare organizations further bolster its earnings by facilitating broader access to its services and enhancing its value proposition in the healthcare market.

Privia Health Group Financial Statement Overview

Summary

Privia Health Group exhibits strong financial performance with significant revenue growth, efficient cost management, and a robust equity base. However, fluctuations in EBIT margins and free cash flow growth warrant attention.

Income Statement

Privia Health Group has shown impressive revenue growth over the years, with the latest figure reaching $1.74 billion, a significant increase from previous years. The gross profit margin is robust, indicating efficient cost management. Despite a slight decline in EBIT and EBITDA margins in the latest year, the company maintains a positive net profit margin, showcasing profitability. However, the fluctuation in EBIT margins could be a point of concern.

Balance Sheet

The company exhibits a strong equity base, with a healthy debt-to-equity ratio indicating low leverage, which is favorable for stability. The return on equity has improved over the years, reflecting effective utilization of shareholder funds. A high equity ratio further underscores financial robustness, though continuous monitoring of debt levels is advised.

Cash Flow

Privia Health Group has demonstrated consistent growth in operating cash flow, which is a positive indicator of cash-generating efficiency. The operating cash flow to net income ratio is strong, suggesting effective conversion of earnings into cash. However, the free cash flow growth rate has experienced some volatility, signaling potential fluctuations in cash availability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.04B	1.74B	1.66B	1.36B	966.22M	817.08M
Gross Profit	202.39M	176.85M	161.50M	134.78M	63.66M	82.58M
EBITDA	41.97M	24.25M	27.18M	-14.55M	-214.97M	27.22M
Net Income	18.17M	14.38M	23.08M	-8.59M	-188.23M	31.24M
Balance Sheet
Total Assets	1.35B	1.14B	999.90M	792.81M	686.37M	328.97M
Cash, Cash Equivalents and Short-Term Investments	441.35M	491.15M	389.51M	347.99M	320.58M	84.63M
Total Debt	6.24M	5.59M	8.29M	11.50M	46.50M	33.66M
Total Liabilities	588.23M	452.34M	392.51M	273.76M	236.19M	185.32M
Stockholders Equity	709.12M	635.18M	561.44M	499.09M	426.87M	146.75M
Cash Flow
Free Cash Flow	110.70M	109.28M	80.67M	47.09M	54.51M	38.51M
Operating Cash Flow	110.70M	109.28M	80.78M	47.20M	55.06M	38.89M
Investing Cash Flow	-96.52M	-11.98M	-42.97M	-104.00K	-32.77M	-380.00K
Financing Cash Flow	5.18M	4.33M	3.71M	-19.68M	213.66M	-767.00K

Privia Health Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 23.43
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRVA, the sentiment is Negative. The current price of 23.43 is below the 20-day moving average (MA) of 25.17, below the 50-day MA of 24.15, and above the 200-day MA of 23.04, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 37.90 is Neutral, neither overbought nor oversold. The STOCH value of 23.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRVA.

Privia Health Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRVA	75 Outperform	$3.03B	211.21	2.74%	―	19.01%	38.68%
HSTM	67 Neutral	$734.21M	36.52	5.87%	0.48%	3.68%	5.62%
PINC	62 Neutral	$2.33B	-102.81	0.42%	2.98%	-21.26%	-119.34%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EVH	49 Neutral	$705.05M	―	-13.63%	―	-16.65%	-71.92%
TDOC	48 Neutral	$1.34B	―	-15.42%	―	-2.37%	77.85%
DH	48 Neutral	$396.10M	-1.05	-47.69%	―	-5.30%	46.01%

Privia Health Group Corporate Events

Privia Health Mourns Loss of Board Member

On October 24, 2025, Patricia Maryland, a member of the Board of Directors and Chair of the Compliance Committee at Privia Health Group, passed away. The company expressed sadness at her passing and gratitude for her significant contributions over the past five years.

The most recent analyst rating on (PRVA) stock is a Buy with a $24.50 price target. To see the full list of analyst forecasts on Privia Health Group stock, see the PRVA Stock Forecast page.

Privia Health Acquires ACO Business for $100 Million

On September 23, 2025, Privia Health Group announced its agreement to acquire an Accountable Care Organization business from Evolent Health for $100 million, with an additional $13 million contingent on performance. This acquisition, expected to close in the fourth quarter of 2025, will expand Privia Health’s value-based care arrangements to approximately 1.5 million attributed lives, enhancing its national network and offering synergy opportunities for participating providers.

The most recent analyst rating on (PRVA) stock is a Buy with a $33.00 price target. To see the full list of analyst forecasts on Privia Health Group stock, see the PRVA Stock Forecast page.

Privia Health Group Announces Significant Medicare Savings

On August 28, 2025, Privia Health Group announced its Accountable Care Organizations (ACOs) achieved $233.1 million in shared savings through the Medicare Shared Savings Program for 2024, marking a 32% increase from the previous year. This performance underscores the effectiveness of Privia’s physician-led approach and data-driven tools, benefiting nearly 195,000 Medicare beneficiaries. The company also increased its Adjusted EBITDA guidance for 2025 to $113-$116 million, reflecting its strong operational performance and strategic positioning in the healthcare industry.

The most recent analyst rating on (PRVA) stock is a Hold with a $21.00 price target. To see the full list of analyst forecasts on Privia Health Group stock, see the PRVA Stock Forecast page.

Privia Health’s Earnings Call Highlights Robust Growth

Privia Health Group, Inc. Reports Strong Growth Amid Cautious Outlook

Privia Health Reports Strong Q2 2025 Financial Results

Privia Health Group, Inc. is a leading physician enablement company in the United States, specializing in building provider networks with primary-care centric medical groups and offering a comprehensive suite of technology and service solutions.